Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced it has completed the training of psychotherapists for its upcoming phase 2a clinical trial using synthetic psilocybin in combination with psychotherapy for overeating disorders. According to the update, the training was conducted by … Continue reading “NetworkNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Completes Psychotherapy Training for Upcoming Clinical Trial”
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, was recently featured as a sponsored content provider on the Visual Capitalist. In the article, part one of a two-part series titled, “The History of Psychedelics (Part 1 of 2),” Tryp … Continue reading “NetworkNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Featured in Visual Capitalist Article”
Delic is led by a best-in-class team of industry veterans with over 100 years of working knowledge in cannabis, finance, and psychedelic research The Vancouver-based company was formed in 2019 as the first psychedelic umbrella platform The Delic self-sustaining Ecosystem covers three main areas: media, health, and science On March 4, 2021, Delic announced its … Continue reading “Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) Is ‘One to Watch’”
Mind Cure Health (CSE: MCUR) (OTCQB: MCURF), a leader in advanced proprietary technology and research for psychedelics, has announced that co-founder and CEO Kelsey Ramsden is featured on the latest episode of the Bell2Bell podcast. The Bell2Bell Podcast offers its listeners insightful interviews with executives of companies operating in fast-moving industries. During the episode, hosted … Continue reading “NetworkNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) Co-Founder, CEO Featured on Bell2Bell Podcast”
Tryp Therapeutics recently announced new agreements with Calvert Labs and Gad Consulting Services, the second in a series of upcoming bridging studies aimed at facilitating the advancement of TRP-8803 into Phase 2b clinical trials Calvert Labs will design and execute the exploratory studies, while Gad Consulting Services will advise on certain aspects of the studies … Continue reading “Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Partners with Calvert Labs, Gad Consulting Services to Conduct Preclinical Bridging Studies in Preparation for Phase 2b Clinical Trials”
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is focused on driving significant innovation with its drug development pipeline. Tryp is leveraging its Psilocybin-for-Neuropsychiatric Disorders (“PFN”) program in the development of treatments for chronic pain indications including fibromyalgia, phantom limb pain and complex regional pain syndrome. In addition, the company is preparing to initiate a phase 2a … Continue reading “NetworkNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Standing Distinct in Psychedelic-Derived Treatments Space”
Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, today announced that Laura Dawn, Msc. will serve as one of the headlining speakers at Meet Delic on Nov. 6, 2021. According to the update, her keynote, “Exploring the Intersection Between Psychedelics & Creative Problem Solving,” targets business and thought-leaders, entrepreneurs and creators. “Laura … Continue reading “NetworkNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) Announces Keynote Speaker for Upcoming Psychedelic and Wellness Event – Meet Delic”
Mr. Greg McKee, CEO of Tryp Therapeutics, appeared on The Dealmaker Podcast to share insights on the company and the psychedelics industry During the interview, he discussed the potential of psychedelics in the treatment of PTSD and other mental disorders Greg also shared the challenges that the industry is facing currently, mostly to do with … Continue reading “Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) CEO Shares Insights on the Psychedelics Space on The Dealmaker Podcast”
Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, today announced that Luke Storey will serve as one of the headline speakers at Meet Delic. The world’s premiere psychedelic and wellness edutainment event, Meet Delic caters to curious newcomers as well as business and thought leaders. A motivational speaker, meditation and metaphysics teacher and lifestyle design … Continue reading “NetworkNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) Announces Headline Speaker for Upcoming Psychedelic and Wellness Event – Meet Delic”
Delic Corp Inc. (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, has announced that Glenn Sammis, a professor and scientific advisor to subsidiary Delic Labs, has received a full professorship at the University of British Columbia in the chemistry department. The announcement also noted that Sammis will be working closely with Dr. Markus Roggen in developing intellectual property (“IP”) … Continue reading “NetworkNewsBreaks – Delic Corp Inc. (CSE: DELC) (OTCQB: DELCF) Scientific Advisor Granted Full Professorship”
